Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial

BACKGROUND: The efficacy and safety of olaparib compared with placebo in the subset of patients from Japan in the phase 3 OlympiA trial (NCT02032823) are reported here and contextualized with reference to the global OlympiA population. METHODS: Patients with germline BRCA1 and/or BRCA2 pathogenic va...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamauchi, Hideko, Toi, Masakazu, Takayama, Shin, Nakamura, Seigo, Takano, Toshimi, Cui, Karen, Campbell, Christine, De Vos, Liesbet, Geyer, Charles, Tutt, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284949/
https://www.ncbi.nlm.nih.gov/pubmed/37005966
http://dx.doi.org/10.1007/s12282-023-01451-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284949/
https://www.ncbi.nlm.nih.gov/pubmed/37005966
http://dx.doi.org/10.1007/s12282-023-01451-8

Ejemplares similares